Skip to content

Clinical study on the efficacy and safety of Shenxiang Qiangxin Decoction for patients with heart failure with heart-kidney Yang deficiency syndrome

Clinical study on the efficacy and safety of Shenxiang Qiangxin Decoction for patients with heart failure with heart-kidney Yang deficiency syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080668
Enrollment
Unknown
Registered
2024-02-04
Start date
2024-02-04
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Shenxiang Qiangxin Decoction group:Shenxiang Qiangxin Decoction + Basic western medicine treatment

Sponsors

Putuo District Central Hospital, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Over 18 years of age, regardless of gender; 2. Meet the diagnostic criteria for chronic heart failure, NYHA heart function grade ?~?; And there is no history of acute attacks within 3 months, and the condition is stable; 3. Left ventricular ejection fraction (LVEF) was < 50%. 4. Those who meet the standard of TCM heart-kidney-yang deficiency differentiation; 5. Subjects must give informed consent to this study before the study, voluntarily sign informed consent, and be able to complete the study as instructed by the doctor.

Exclusion criteria

Exclusion criteria: 1. Patients with acute decompensation of chronic heart failure, whose expected survival time is less than 3 months; 2. There are mental abnormalities or can not insist on taking Chinese medicine; 3. Pregnant and lactating women who have previously been found to be allergic to the test drug; 4. There are factors that can increase death: such as severe arrhythmia, pulmonary embolism, cardiogenic shock, obvious infection, and hypertensive patients with blood pressure above grade 2 (blood pressure > 160/100mmHg) after antihypertensive treatment.

Design outcomes

Primary

MeasureTime frame
Six-minute walk distance;Left ventricular ejection fraction;

Secondary

MeasureTime frame
NT-proBNP;TCM symptom score;Minnesota heart failure quality of life questionnaire;

Countries

China

Contacts

Public ContactLiu Zongjun

Putuo District Central Hospital, Shanghai

liuzongjun1548@shutcm.edu.cn+86 198 2157 7439

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026